InflaRx NV (STU:IF0)
€ 2.022 0 (0%) Market Cap: 141.14 Mil Enterprise Value: 84.15 Mil PE Ratio: 0 PB Ratio: 2.04 GF Score: 38/100

Inflarx NV at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 12:30PM GMT
Release Date Price: €4.95 (-3.90%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior analysts at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is InflaRx, and speaking on behalf of the company, we have CEO, Niels Riedemann.

(Operator Instructions)

With that, I'll pass it over to Niels. Niels?

Niels C. Riedemann
InflaRx N.V. - Co-Founder, CEO & Executive Director

Well, thanks so much, Anupam. Much appreciated. Thanks for inviting us to your exciting conference, and I have to give you an update on what's going on with InflaRx. So I'd like to briefly direct you to the cautionary note regarding forward-looking statements since we are a public company. So I'll move through the slide deck and will tell you where I am, so for those of you -- to be able to follow online where we are.

So on Page 3, investment highlights. So we are really focusing on terminal complement inhibition with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot